Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating

On March 23, 2026, BeOne Medicines AG (NASDAQ:ONC) received orphan cause designation from the FDA for its hepatocellular carcinoma treatment.

On March 16, 2026, Jefferies expert Faisal Khurshid downgraded BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy with a $290 terms target, down from $420, stating that portion Brukinsa remains a starring hematology asset, the banal “is not mispriced” astatine existent levels. The steadfast added that enactment successful chronic lymphocytic leukemia is already reflected, with aboriginal maturation drivers expected to play retired much gradually.

BeOne Medicines AG (NASDAQ:ONC) develops oncology treatments crossed planetary markets.

While we admit the imaginable of ONC arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.